PubMed
Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018
Compare
GLOW Blend vs Tesamorelin
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
GLOW Blend
1281 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 45% · Mixed 38% · Unfavorable overall 17%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Skin appearance
68
Appetite control
19
Energy
170
Mood
189
Focus
124
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
164
GI discomfort
98
Dizziness
135
Fatigue
184
Nausea
123
Self-reported dose per injection
Median bucket: 200–400 mcg · Most common: 200–400 mcg
Reports span 50–1000 mcg
50–100
7
100–200
11
200–400
21
400–600
11
600–1000
7
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Common discussion topics
timing45stacking28side effects11glow blend14
How repeat users are trending
Among repeat reporters, 55% said they felt similar to their last entry, 43% more positive, and 15% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 32 days · Based on 282 repeat reporters
Tesamorelin
114 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
224
Sleep
1
Recovery
1
Libido
1
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
113
Water retention
106
Self-reported dose per injection
Median bucket: 1–2 mg · Most common: 1–2 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
9
0.1–0.2 mg
1
0.2–0.4 mg
5
0.4–0.6 mg
5
0.6–1 mg
4
1–2 mg
126
2–3 mg
74
5+ mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 12% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 46 days · Based on 41 repeat reporters
Sources (8)
Published sources linked on the GLOW Blend and Tesamorelin wiki pages.
- Wiki study page →Source
- Wiki study page →Source
Review Article
GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes
Pickart L, Margolina A. Cosmetics. 2018
- Wiki study page →Source
FDA Drug Label
EGRIFTA (tesamorelin) for injection - Prescribing Information
Theratechnologies. FDA Drug Label. 2010
- Wiki study page →Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo E, Arvat E, Camanni F. Endocrine. 2008
- Wiki study page →Source
ClinicalTrials.gov
Tesamorelin HIV lipodystrophy studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
FDA Drug Label
EGRIFTA SV (tesamorelin) for injection - Prescribing Information
Theratechnologies. FDA Drug Label. 2019
- Wiki study page →Source
PubMed
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy
Spooner LM, Olin JL. The Annals of pharmacotherapy. 2012
- Wiki study page →Source
PubMed
Tesamorelin
2018